Gibson Dunn has advised Denali Therapeutics. Goodwin Procter and Maiwald have advised Royalty Pharma. Denali Therapeutics Inc. (Nasdaq: DNL) and Royalty Pharma plc (Nasdaq: RPRX) have...
Denali Therapeutics Enters $275 Million Synthetic Royalty Funding Agreement with Royalty Pharma
Zenas BioPharma Secures Up to $300 Million Synthetic Royalty Financing from Royalty Pharma
Ropes & Gray has advised Zenas BioPharma on the transaction, and Goodwin Procter and Maiwald GmbH have advised Royalty Pharma. Zenas BioPharma has entered into a...
Geron Corporation’s $375 Million Funding
Fenwick & West represented Royalty Pharma in the transaction. Geron Corporation (Nasdaq: GERN) announced that Royalty Pharma (Nasdaq: PRRX), a buyer of biopharmaceutical royalties and funder...
Royalty Pharma’s $150 Million Royalty Funding Agreement with Ascendis Pharma
Fenwick & West and Goodwin Procter represented Royalty Pharma plc in the transaction, and Latham & Watkins and Mazanti-Andersen represented Ascendis Pharma A/S. Ascendis Pharma A/S...
Novocure’s $400 Million Multi-Tranche Non-Dilutive Debt Financing
Fenwick & West represented Pharmakon Advisors in the transaction. Novocure (NASDAQ: NVCR) announced today that it has entered into a new five-year up to $400 million...
Alumis’ $259 Million Series C Financing Round
Fenwick & West represented Samsara BioCapital in the transaction. Alumis Inc. announced an upsized $259M Series C financing round co-led by existing investor, Foresite Capital, and new...
Royalty Pharma’s $1.5 Billion Acquisition of PTC Therapeutics’ Royalties
Fenwick & West, Goodwin Procter and Maiwald represented Royalty Pharma in the transaction, Wilmer Cutler Pickering Hale and Dorr represented PTC Therapeutics. Royalty Pharma plc (Nasdaq:...
Ascendis Pharma’s $150 Million Royalty Funding Agreement with Royalty Pharma
Latham & Watkins and Mazanti-Andersen acted as legal advisors to Ascendis on the transaction, while Goodwin Procter, Kromann Reumert and Fenwick & West acted as legal...
Royalty Pharma $500 Million Royalty Agreement with Ferring Pharmaceuticals
Fenwick & West represented Royalty Pharma, and Orrick Herrington & Sutcliffe represented Ferring Pharmaceuticals in the deal. Royalty Pharma plc (Nasdaq: RPRX) and Ferring Pharmaceuticals announced...
Royalty Pharma’s Acquisition of Royalty Interest in SPINRAZA and Pelacarsen from Ionis
Fenwick and Goodwin represented Royalty Pharma on the deal. Royalty Pharma (Nasdaq: RPRX), a buyer of biopharmaceutical royalties and funder of innovation across the biopharmaceutical industry,...
Pharmakon’s Loan Agreement with Immunocore
Fenwick advised Pharmakon on the deal while Akin Gump advised Pharmakon Advisors. Pharmakon, an investor in non-dilutive debt for the life sciences industry and the investment...
Royalty Pharma’s Interest Acquisition in Amgen’s Olpasiran
Fenwick represented Royalty Pharma on the deal. Royalty Pharma (Nasdaq: RPRX), a buyer of biopharmaceutical royalties and funder of innovation across the biopharmaceutical industry, announced the...